Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Definitive chemoradiotherapy is the standard of care in unresectable esophageal or
esophagogastric cancer. A multidisciplinary approach, including chemotherapy and
radiotherapy, is important for these patients. Morerover, molecular targeting agents does not
show clear efficacy in EC up to now. Nowadays, the pace of development of cancer
immunotherapies is accelerating. Clinical evidence of the efficacy of immune checkpoint
inhibitors and adoptive immunotherapies herald the onset of a new era in cancer
immunotherapy. There have also been recent developments to provide a promising frontier in
extending the use of immunotherpay or targeting agents to radiotherapy. The purpose of this
study was to explore the optimal treatment modalities including PD-1/PD-L1 antibody or
targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.